Evidence map›Paper›PMID 32498707›Full record

SynthesisBMC medicine2020

Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOrT) metric for a personalised psychiatry.

Nils Kappelmann, Martin Rein, Julia Fietz, Helen S Mayberg, W Edward Craighead, Boadie W Dunlop, Charles B Nemeroff, Martin Keller, Daniel N Klein, Bruce A Arnow and 11 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in BMC medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Understanding symptom profiles of depression with the PHQ-9 in a community sample using network analysis.European psychiatry : the journal of the Association of European Psychiatrists · 2024
    Article
  8. Review
  9. Article
  10. From Mental Health Industry to Humane Care. Suggestions for an Alternative Systemic Approach to Distress.International journal of environmental research and public health · 2021
    Review
  11. Moving toward a process-oriented perspective in the personalized treatment of depression.European archives of psychiatry and clinical neuroscience · 2021
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 6 countries.

Nils KappelmannMax Planck Institute of Psychiatry, Kraepelinstraße 2-10, 80804, Munich, Germany. nils_kappelmann@psych.mpg.de.ORCID 0000-0002-2923-4455
Martin ReinMax Planck Institute of Psychiatry, Kraepelinstraße 2-10, 80804, Munich, Germany.
Julia FietzMax Planck Institute of Psychiatry, Kraepelinstraße 2-10, 80804, Munich, Germany.
Helen S MaybergDepartment of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
W Edward CraigheadDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.
Boadie W DunlopDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.
Charles B NemeroffInstitute for Early Life Adversity Research, University of Texas Dell Medical School in Austin, Austin, TX, USA.
Martin KellerDepartment of Psychiatry and Human Behavior, Brown University School of Medicine, Providence, RI, USA.
Daniel N KleinDepartment of Psychology, Stony Brook University, Stony Brook, NY, USA.
Bruce A ArnowDepartment of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94304, USA.
Nusrat HusainDivision of Psychology and Mental Health, The University of Manchester, Manchester, UK.
Robin B JarrettDepartment of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jeffrey R VittenglDepartment of Psychology, Truman State University, Kirksville, MO, USA.
Marco MenchettiDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Gordon ParkerSchool of Psychiatry, University of New South Wales, Sydney, NSW, Australia.
Jacques P BarberGordon F. Derner School of Psychology, Adelphi University, Garden City, New York, USA.
Andre G BastosContemporary Institute of Psychoanalysis and Transdisciplinarity of Porto Alegre, Porto Alegre, Brazil.
Jack DekkerDepartment of Research, Arkin Mental Health Care, Amsterdam, Netherlands.
Jaap PeenDepartment of Research, Arkin Mental Health Care, Amsterdam, Netherlands.
Martin E KeckMax Planck Institute of Psychiatry, Kraepelinstraße 2-10, 80804, Munich, Germany.
Johannes Kopf-BeckMax Planck Institute of Psychiatry, Kraepelinstraße 2-10, 80804, Munich, Germany.
Max Planck Institute of Psychiatry · DEEmory University · USArkin · NLAdelphi University · USBrown University · USStanford University · USStony Brook University · USThe University of Texas Southwestern Medical Center · USTruman State University · USUniversity of Bologna · ITUniversity of Manchester · GBUNSW Sydney · AU

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
X LINKED NYSTAGMUS SYNDROME WITH FEATURES OF ALBINISMM01RR000039 · NCRR · EMORY UNIVERSITY · PI QUYYUMI, ARSHED A · 1985 to 2007
$21.3M
Special Scientific Procedures: Statistical Modeling CoreP50MH077083 · NIMH · EMORY UNIVERSITY · PI KUTNER, MICHAEL HENRY · 2006 to 2010
$9.3M
Predictors of Treatment Response Relapse and Recurrence in Major DepressionR01MH080880 · NIMH · EMORY UNIVERSITY · PI CRAIGHEAD, W. EDWARD · 2008 to 2012
$6.6M
Testing an Imaging Biomarker for Treatment Stratification in Major DepressionR01MH073719 · NIMH · EMORY UNIVERSITY · PI DUNLOP, BOADIE W · 2006 to 2018
$5.8M
EFFICACY OF DYNAMIC THERAPY VS SSRI FOR DEPRESSIONR01MH061410 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI BARBER, JACQUES P · 2001 to 2005
$3.3M
TRAINING PROGRAM IN TISSUE REPAIRT32GM008695 · NIGMS · VIRGINIA COMMONWEALTH UNIVERSITY · PI DIEGELMANN, ROBERT F · 1998 to 2009
$958k
Investigating structural-functional brain abnormalities in late-life depressionK23MH077869 · NIMH · EMORY UNIVERSITY · PI HOLTZHEIMER, PAUL E · 2007 to 2010
$687k
Neural Correlates of Loss Aversion in Major DepressionK23MH086690 · NIMH · EMORY UNIVERSITY · PI DUNLOP, BOADIE W · 2009 to 2011
$521k
Bundesministerium für Bildung und Forschung 01EE1401DBundesministerium für Bildung und Forschung (DE) 01ES0811Foundation for the National Institutes of Health M01 RR0039NCRR NIH HHS M01 RR000039NCRR NIH HHS UL1 RR025008NIGMS NIH HHS T32 GM008695NIMH NIH HHS K23 MH077869NIMH NIH HHS K23 MH086690NIMH NIH HHS P50 MH077083NIMH NIH HHS R01 MH061410NIMH NIH HHS R01 MH073719NIMH NIH HHS R01 MH080880
6 · The paper itself

Abstract

backgroundAntidepressant medication (ADM) and psychotherapy are effective treatments for major depressive disorder (MDD). It is unclear, however, if treatments differ in their effectiveness at the symptom level and whether symptom information can be utilised to inform treatment allocation. The present study synthesises comparative effectiveness information from randomised controlled trials (RCTs) of ADM versus psychotherapy for MDD at the symptom level and develops and tests the Symptom-Oriented Therapy (SOrT) metric for precision treatment allocation.

methodsFirst, we conducted systematic review and meta-analyses of RCTs comparing ADM and psychotherapy at the individual symptom level. We searched PubMed Medline, PsycINFO, and the Cochrane Central Register of Controlled Trials databases, a database specific for psychotherapy RCTs, and looked for unpublished RCTs. Random-effects meta-analyses were applied on sum-scores and for individual symptoms for the Hamilton Rating Scale for Depression (HAM-D) and Beck Depression Inventory (BDI) measures. Second, we computed the SOrT metric, which combines meta-analytic effect sizes with patients' symptom profiles. The SOrT metric was evaluated using data from the Munich Antidepressant Response Signature (MARS) study (n = 407) and the Emory Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study (n = 234).

resultsThe systematic review identified 38 RCTs for qualitative inclusion, 27 and 19 for quantitative inclusion at the sum-score level, and 9 and 4 for quantitative inclusion on individual symptom level for the HAM-D and BDI, respectively. Neither meta-analytic strategy revealed significant differences in the effectiveness of ADM and psychotherapy across the two depression measures. The SOrT metric did not show meaningful associations with other clinical variables in the MARS sample, and there was no indication of utility of the metric for better treatment allocation from PReDICT data.

conclusionsThis registered report showed no differences of ADM and psychotherapy for the treatment of MDD at sum-score and symptom levels. Symptom-based metrics such as the proposed SOrT metric do not inform allocation to these treatments, but predictive value of symptom information requires further testing for other treatment comparisons.

Indexed as

Antidepressive AgentsCombined Modality TherapyDepressionFemaleHumansMalePsychotherapyTreatment OutcomeAntidepressive AgentsAntidepressant medicationDepression symptomsMajor depressive disorderMeta-analysisPrecision psychiatryPsychotherapySymptom-oriented therapy metricSystematic review

Identifiers

PMID32498707
PMCPMC7273646
OpenAlexW3033549307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.